Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.32 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714128 | 0.88 | SCN9A (0.39) | SCN9AGABRA5MAPTCYP17A1GSK3B | |
| SCHEMBL2714373 | 0.85 | ATM (0.43) | SCN9AGABRA5MAPTLMNAPOLB | |
| SCHEMBL2713773 | 0.84 | SCN9A (0.45) | SCN9A | |
| SCHEMBL2715597 | 0.84 | MAPT (0.38) | SCN9AACACBMAPTLMNAPOLB | |
| SCHEMBL2716368 | 0.82 | LMNA (0.42) | SCN9AACACBMAPTLMNAPOLB | |
| SCHEMBL2717826 | 0.81 | HCRTR1 (0.36) | SCN9AGABRA5MAPTCYP17A1GSK3B | |
| SCHEMBL2716486 | 0.80 | MAPK1 (0.41) | SCN9AMAPTLMNAPOLBNPSR1 | |
| SCHEMBL2715349 | 0.79 | SCN9A (0.43) | SCN9AACACBHCRTR2 | |
| SCHEMBL2716201 | 0.79 | L3MBTL1 (0.43) | SCN9APOLBAAK1 | |
| SCHEMBL15351020 | 0.78 | SSTR4 (0.41) | SCN9AMAPTGSK3BMKNK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944634-B2 | Pyrazolopyridine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9187475-B2 | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2914597-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2014068988-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | SCN9A 53/4885GABRA5 163/4885ACACB 3453/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | SCN9A 31/4885GABRA5 140/4885ACACB 1601/4885 |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, KCNH2, CACNA1G | SCN9A 66/4885GABRA5 209/4885ACACB 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.